Clinical Trial: The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-dideoxyinosine or 2',3'-dideoxycytidine in Patients with Human Immunodeficiency Virus Disease

This study has been completed.

Sponsored by: Glaxo Wellcome
Information provided by: AIDS Clinical Trials Information Service

Purpose

To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety and the tolerance of the coadministration of zidovudine and ddI or ddC.

Condition Treatment or Intervention
HIV Infections
 Drug: Zidovudine
 Drug: Zalcitabine
 Drug: Didanosine

MedlinePlus related topics:  AIDS

Study Type: Interventional
Study Design: Treatment, Double-Blind, Safety Study

Eligibility

Ages Eligible for Study:  13 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Concurrent Medication: Allowed:

  • Patients with PCP may be randomized to study medication after contacting the sponsor and following a minimum 7-day course of therapy resulting in stabilization of their disease. Patients with stabilized disease must have fever < 39 C for at least 48 hours, p02 (on room air) > or = 60 mm and an A/A gradient < or = 30 mm.
  • Prophylaxis for PCP. Patients must have the following:
  • HIV-1 seropositive by any federally licensed ELISA.
  • Willingness to give informed consent.

Exclusion Criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded:

  • Any immediately life-threatening infection or medical condition present at time of study entry.
  • Any active opportunistic infection requiring chronic therapy with any of the agents listed in the exclusion concurrent medication section.
  • Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.
  • Kaposi's sarcoma with visceral involvement or requiring systemic cytotoxic chemotherapy.
  • AIDS dementia complex, > or = Stage 2.
  • History of zidovudine induced toxicity.
  • Prior history of acute pancreatitis during the past two years or chronic pancreatitis.
  • Grade 2 neuropathy.
  • Intractable diarrhea.
  • History of seizures within the past six months or current requirement of anticonvulsants.
  • Past or current heart disease.
  • Fever > 39 C at entry. Concurrent Medication: Current requirement of anticonvulsants.
  • Excluded:
  • It is intended that patients developing new opportunistic infections during the course of the study will continue study participation, unless required therapy is associated with significant neurologic or hematologic toxicities, in which case the study medication may be temporarily discontinued.
  • Ganciclovir.
  • Chloramphenicol.
  • Cisplatinum.
  • Iodoquinol.
  • Systemic Pentamidine.
  • Disulfiram.
  • Ethionamide.
  • Glutethimide.
  • Gold.
  • Hydralazine.
  • Metronidazole.
  • Sodium Cyanate.
  • Thalidomide.
  • Vincristine.
  • Allopurinol.
  • Probenecid.

Concurrent Treatment: Excluded:

Patients with the following are excluded:

  • Any immediately life-threatening infection or medical condition present at time of study entry.
  • Any active opportunistic infection requiring chronic therapy with any of the agents listed in the exclusion concurrent medication section.
  • Active alcohol or drug abuse, sufficient in the investigator's opinion to prevent compliance with study therapy.
  • Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.
  • Kaposi's syndrome with visceral involvement or requiring systemic cytotoxic chemotherapy.
  • AIDS dementia complex, > or = Stage 2.
  • History of zidovudine induced toxicity.
  • Any experimental therapy within 30 days.
  • Prior history of acute pancreatitis during the past two years or chronic pancreatitis.
  • Grade 2 neuropathy.
  • Intractable diarrhea.
  • History of seizures within the past six months or current requirement of anticonvulsants.
  • History of past or current heart disease.
  • Fever > 39 C at entry.

Prior Medication: Excluded:

  • Any anti-HIV therapy (other than zidovudine), biologic response modifiers, or pharmacologic doses of corticosteroids within eight weeks of entry (except for the management of severe PCP, in which case duration is not to exceed 21 days).
  • Zidovudine therapy for greater than four weeks or prior discontinuation due to drug toxicity.
  • Prior therapy with ddI, ddC, D4T, or interferon.
  • Any experimental therapy within 30 days.
  • Therapy within 30 days with neurotoxic drugs.

Prior Treatment: Excluded:

Active alcohol or drug abuse, sufficient in the investigator's opinion, to prevent compliance with study therapy.


Location Information


Colorado
      Univ of Colorado Health Sciences Ctr, Denver,  Colorado,  80262,  United States

District of Columbia
      Georgetown Univ Med Ctr / Main Hosp 4, Washington,  District of Columbia,  20007,  United States

Tennessee
      Vanderbilt School of Medicine, Nashville,  Tennessee,  37232,  United States

Australia
      Saint Vincent's Hosp Med Centre, Darlinghurst,  Australia

Puerto Rico
      San Juan Veterans Administration Med Ctr, San Juan,  009275800,  Puerto Rico

More Information

Publications

Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996 Sep;70(9):5922-9.

Study ID Numbers:  052B; 02
Record last reviewed:  September 1991
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002001
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources